Skip to main content
. 2013 Jun 7;5:91–101. doi: 10.2147/CMAR.S32973

Table 3.

Anaplastic lymphoma kinase (ALK) inhibitors in early clinical development for treatment of ALK rearrangement-positive non-small-cell lung cancer

Inhibitor Phase Company References
CH5424802 II Chugai 93,94
LDK378 I Novartis 95
ASP3026 I Astellas Pharma 100
AP26113 I/II Ariad 98
X396 I Xcovery 99